No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy

Abstract

The steady-state serum albumin binding of VPA in Japanese patients with epilepsy is not affected by co-administration of other antiepileptic drugs. These findings suggest that serum VPA concentration is stable at the steady state with regard to interaction by protein binding, even when other antiepileptic drugs with moderate-to-high binding properties are co-administered.

Valproic acid disrupts the biomechanics of late spinal neural tube closure in mouse embryos

“…Caudal spina bifida similar to that seen in humans can be induced in mice by repeated exposure to VPA during mid to late spinal neurulation (three injections on E9) ( Ehlers et al, 1992 ). In cultured rodent embryos, exposure to ~ 1 mM VPA, which is comparable to concentrations measured in the blood of human patients ( Suzuki et al, 2011 , Vasudev et al, 2001 ), causes cranial and/or spinal NT defects depending on the treatment regime ( Lampen et al, 1999 , Seegmiller et al, 1991 ). However, embryos from certain mouse strains have been reported to be more sensitive to the teratogenic effects of VPA both in vivo ( Lundberg et al, 2004 ) and in culture ( Naruse et al, 1988 ).…”

Harnessing the power of natural alkaloids: the emergent role in epilepsy therapy

“…Consequently, further empirical scrutiny into the toxicological profiles and the safety of natural alkaloids is imperative. Prospective research trajectories should pivot on the explication of underlying molecular pathways, the longitudinal assessment of efficacy and safety in controlled human studies, thereby bridging the gap towards the incorporation of these alkaloids into mainstream epilepsy therapeutics ( Suzuki et al, 2011 ).…”